Evidence map›Paper›PMID 38965630›Full record

ArticleBMC chemistry2024

6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation.

Leila Emami, Maryam Hassani, Pegah Mardaneh, Fateme Zare, Maryam Saeedi, Mina Emami, Soghra Khabnadideh, Sara Sadeghian

Abstract read
In one paragraph

Article in BMC chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leila EmamiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam HassaniDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Pegah MardanehDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Fateme ZarePharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam SaeediDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Mina EmamiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Soghra KhabnadidehPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. khabns@sums.ac.ir.
Sara SadeghianDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. s_sadeghian@sums.ac.ir.

Funding

Shiraz Transplant Research Center, Shiraz University of Medical Sciences 28186
6 · The paper itself

Abstract

Based on unselectively, several side effects and drug resistance of available anticancer agents, the development and research for novel anticancer agents is necessary. In this study, a new series of quinazoline-4(3H)-one derivatives having a thiol group at position 2 of the quinazoline ring (8a-8 h) were designed and synthesized as potential anticancer agents. The Chemical structures of all compounds were characterized by

Indexed as

CancerDFTDockingMDMTTQuinazoline-4(3H)-one

Identifiers

PMID38965630
PMCPMC11225515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.